Pharmacogenomics Market Size & Analysis | Report 2021, 2028

Pharmacogenomics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (PCR, Sequencing, Microarray, Gel Electrophoresis, Mass Spectrometry, and Others), Application (Drug Discovery, Oncology, Neurology and Psychiatry, Pain Management, Cardiovascular Diseases, and Others), and End User (Hospitals and Clinics, Biopharmaceutical Companies, CROs and CDMOs, and Others)

Publication Month: Feb 2022 | Report Code: TIPRE00007564 | No. of Pages: 239 | Category: Biotechnology | Status: Published

The pharmacogenomics market is projected to reach US$ 14,107.80 million by 2028 from US$ 7,087.81 million in 2021; it is expected to grow at a CAGR of 10.3% from 2021 to 2028.

The increasing prevalence of chronic diseases is one of the most critical factors driving the growth of the market. Many older adults (>60%) suffer from two or more chronic conditions. Twin studies stated that genes can cause chronic conditions, such as cardiovascular disease (CVDs), diabetes, obesity, RA, Alzheimer's disease (AD), and depression. Using molecular genetic data from genome-wide association studies (GWAS), it is now possible to measure individual-level risks for these chronic diseases. According to the Centers for Disease Control and Prevention (CDC), in 2020, nearly 6 in 10 people in the US suffered from at least one chronic disease, and 4 in 10 people had two or more chronic conditions.The increasing incidence of chronic diseases is triggering the demand of pharmacogenomic technologies for developing novel therapies.

Strategic Insights


North America is likely to dominate the pharmacogenomics market during 2021–2028. The US holds the largest share of the market in North America and is expected to continue this trend during the forecast period. The pharmacogenomics market in the US is expected to grow in the coming years due to rising research activities for developing precision medicine to treat cancer, increasing presence of leading biopharmaceutical and pharmaceutical companies, and growing pharmacogenomic research in the country. The adoption rate of pharmacogenomics-based cancer treatment is rising continuously, and the leading market players are introducing several novel products associated with this approach. Also, the support of the regulatory agencies is expected to drive the market in the US during the forecast period. Currently, several clinical trials are investigating pharmacogenomics technology for developing precise medications and improving the overall response rate of the treatment. In May 2021, US Food and Drug Administration (FDA) approved Lumakras (Sotorasib) for a targeted therapy for non-small cell lung cancer patients with tumors that express the G12C mutation in the KRAS gene.

Lucrative Regions for Pharmacogenomics Market

Lucrative Regions for Pharmacogenomics Market

Get more information on this report :


Market Insights

Growing Funding for Pharmacogenomic Research Drives Market Growth

Genomic sequencing is increasingly used in clinical practice, and over the next five years, genomic data from over 60 million patients are expected to be generated within the healthcare system. Pharmacogenomics is rapidly transitioning into clinical practice, and implementation into healthcare systems supported by government investment is totaling over US$ 4 billion in at least 14 countries.

The UK has announced the world’s largest genome project as a part of EURO200 million public–private collaboration between charities and pharma. The country has already developed the largest genome database in the world through the 100,000 genome projects led by Innovate UK as a part of the UK Research and Innovation. The project will fund researchers and industries to combine data and real-world evidence from the UK healthcare services and create new products and services that can diagnose diseases efficiently.

Moreover, in August 2018, Boston Scientific Corporation, a Massachusetts-based company, announced it landed US$ 4.3 million in seed funding and partnered with Veritas Genetics. The funds will support the company’s mission to enter the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data.

Technology-Based Insights

Based on technology, the pharmacogenomics market is segmented into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. The market for the PCR segment is further segmented into standard PCR, real time PCR, and digital PCR. The PCR segment is expected to account for the largest share of the pharmacogenomics market during 2021–2028. Polymerase chain reaction (PCR) is a commonly used technology to rapidly producemillions to billions of copies of a specific DNA sample, allowing scientists to take a small sample of DNA and amplify it to a significant enough amount to investigate in detail. The PCR technologies plays a key role in gene cloning and manipulation, DNA cloning, gene mutagenesis, functional analysis of gene, detection of pathogens, and drug resistence assay. Various pharmaceutical and biopharmaceutical companies offer PCR solutions for pharmacogenomic and drug development applications. For instance, Thermo Fisher Scientific, Inc offers real time PCR solutions for the pharmacogenomic application.

Pharmacogenomics Market, by Technology – 2021 and 2028

Pharmacogenomics Market, by Technology – 2021 and 2028

Get more information on this report :


Application – Based Insights

Based on application, the pharmacogenomics market is segmented into drug discovery, oncology, neurology and psychiatry, pain management, cardiovascular diseases, and others. The oncology segment holds a considerable market share and is projected to continue its dominance during the forecast period. Cancer pharmacogenomics has contributed several essential discoveries to current cancer treatment, changing the paradigm of treatment decisions. World Health Organization (WHO) stated that cancer reckoned for roughly 10 million demises in 2020. Furthermore, as per the data of American Cancer Society, the global burden of carcinoma is anticipated to rise to 27.5 million fresh cases and 16.3 million cancer deaths by year 2040. Such high figures denote that the rising incidence of cancer is creating a requirement for primitive diagnosis and preventive cure. There are numerous methods, such as PCR, INAAT, and NGS, to diagnose carcinoma comprehending. The conception of PCR (polymerase chain reaction) led to an enormous advancement in clinical DNA testing. PCR-based methodologies demand straightforward instrumentation and infrastructure, exploit only minute quantities of biological material, and are extensively harmonious with clinical routine. The application of pharmacogenomics in oncology is significant because of the tapered therapeutic index of chemotherapeutic drugs and the risk for life-threatening adverse effects.

End User – Based Insights

Based on end user, the pharmacogenomics market is segmented into hospitals and clinics, biopharmaceutical companies, CROs and CDMOs, and others. The CROs and CDMOs segment holds a considerable market share and is projected to continue its dominance during the forecast period. The contract research organization (CRO) helps various companies and organization by conducting the clinical trial of their developed products and technologies, whereas the contract development and manufacturing organizations (CDMO) assist the companies in development and manufacturing of the products. The CROs offer services, such as project management, database design and build, data entry and validation, clinical trial data management, medicine and disease coding, quality and metric reporting, statistical analysis plans and reports, validation programming, and safety and efficacy summaries and final study reports. CROs alsoprovides some other services such as gene services, cloning services, and expression.

Companies operating in the pharmacogenomics market adopt the inorganic growth strategy to meet the evolving customer demands across the world, which involves acquisitions, mergers, and collaborations with local and international players in the global market.

Pharmacogenomics Market – Segmentation

  • Based on technology, the pharmacogenomics market is segmented into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. The market for the PCR segment is further segmented into standard PCR, real time PCR, and digital PCR.
  • By application, the pharmacogenomics market is segmented into drug discovery, oncology, neurology and psychiatry, pain management, cardiovascular diseases, and others.
  • Based on end User, the pharmacogenomics market is segmented into hospitals and clinics, biopharmaceutical companies, CROs and CDMOs, and others.
  • By Geography, the intradermal injection market is segmented in North America (the US, Canada, and Mexico), Europe (France, Germany, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (Australia, China, India, Japan, South Korea, and the Rest of APAC), Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of MEA), and South and Central America (Brazil, Argentina, and the Rest of SCAM).

F. Hoffmann-la Roche Ltd; Abbott; Oxford Nanopore Technologies; Thermo Fisher Scientific Inc; Illumina, Inc; QIAGEN; Agilent Technologies, Inc; Myriad Genetics, Inc; Admera Health; and Dynamic DNA Laboratories are a few companies operating in the pharmacogenomic market.

Frequently Asked Questions

Pharmacogenomics is a branch of science, which studies the role of gene over the activity of a drugs and hence helps the refreshers in predicting the response of novel as well as previously available therapies. Pharmacogenomics has direct application in the development of personalized medicine by testing single or multiple genes that are related to the disease. The main aim of this technology is to reduce the occurrence of treatment related adverse events and reduction in overall cost of treatment. The growing cases of ADRs and increasing demand of personalized therapies are expected to trigger the growth rate of this segment.
Several factors are believed to affect pharmacogenomics market in the coming years. Factors such as growing adoption of personalized therapies, increasing prevalence of chronic diseases, and growing funding in this sector are driving the market growth. However, lack of skilled professionals is likely to hamper the growth of the market.
The pharmacogenomics market majorly consists of the players such as F. Hoffmann-la Roche Ltd; Abbott; Oxford Nanopore Technologies; Thermo Fisher Scientific Inc.; Illumina, Inc.; QIAGEN; Agilent Technologies, Inc.; Myriad Genetics, Inc.; Admera Health; Dynamic DNA Laboratories among others..
The global pharmacogenomics market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The North American area holds the largest market for pharmacogenomics. The United States held the most significant pharmacogenomics market and is expected to grow due to factors such as the increasing prevalence of chronic diseases and growing investments while the technological advancements by key players in pharmacogenomics is also boosting the growth rate in US. The Asia Pacific region is expected to account for the fastest growth in the pharmacogenomics market. In Japan, India and South Korea, the market is expected to grow owing to the rapid development of research organizations and biopharmaceutical companies.
The global pharmacogenomics market based on technology is segmented into sequencing, PCR, gel electrophoresis, mass spectrometry, microarray, and others. In 2021, the PCR segment held the largest share of the market by technology and it is expected to witness fastest CAGR during 2021 to 2028, due to increasing utilization of this technology at global level.

1. Introduction 29

1.1 Scope of the Study. 29

1.2 The Insight Partners Research Report Guidance. 29

1.3 Market Segmentation. 30

1.3.1 Global Pharmacogenomics Market – By Technology. 31

1.3.2 Global Pharmacogenomics Market – By Application. 32

1.3.3 Global Pharmacogenomics Market – By End User. 32

1.3.4 Global Pharmacogenomics Market – By Geography. 32

2. Key Takeaways 34

3. Research Methodology 40

3.1 Coverage. 41

3.2 Secondary Research. 41

3.3 Primary Research. 41

4. Pharmacogenomics Market – Market Landscape 43

4.1 Overview. 43

4.2 PEST Analysis. 43

4.2.1 North America PEST Analysis. 43

4.2.2 Europe PEST Analysis. 44

4.2.3 Asia Pacific PEST Analysis. 44

4.2.4 Middle East And Africa PEST Analysis. 45

4.2.5 South And Central America PEST Analysis. 45

4.3 Experts Opinion. 46

5. Pharmacogenomics Market – Key Market Dynamics 47

5.1 Market Drivers. 47

5.1.1 Increasing Prevalence of Chronic Diseases. 47

5.1.2 Growing Funding for Pharmacogenomics. 47

5.2 Market Restraints. 48

5.2.1 Lack of Skilled Professionals. 48

5.3 Market Opportunities. 48

5.3.1 Increasing Demand for Third Generation Sequencing. 48

5.4 Future Trends. 49

5.4.1 Increasing Demand for Personalized Medicines. 49

6. Pharmacogenomics Market– Global Analysis 50

6.1 Global Pharmacogenomics Market Revenue Forecast and Analysis. 50

6.2 Global Pharmacogenomics Market, By Geography - Forecast and Analysis. 51

6.3 Market Positioning of Key Players. 51

7. Pharmacogenomics Market Revenue and Forecasts To 2028 – Technology 53

7.1 Overview. 53

7.2 Global Pharmacogenomics Market Share by Technology - 2021 & 2028 (%) 53

7.3 Polymerase Chain Reaction. 54

7.3.1 Overview.. 54

7.3.2 Polymerase Chain Reaction: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 54

7.3.3 Real Time PCR.. 55

7.3.3.1 Overview.. 55

7.3.3.2 Real Time PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 55

7.3.4 Standard PCR.. 56

7.3.4.1 Overview.. 56

7.3.4.2 Standard PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 56

7.3.5 Digital PCR.. 56

7.3.5.1 Overview.. 56

7.3.5.2 Digital PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 57

7.4 Sequencing. 58

7.4.1 Overview.. 58

7.4.2 Sequencing: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 59

7.5 Microarray. 60

7.5.1 Overview.. 60

7.5.2 Microarray: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 60

7.6 Gel Electrophoresis. 61

7.6.1 Overview.. 61

7.6.2 Gel Electrophoresis: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 61

7.7 Mass Spectrometry. 62

7.7.1 Overview.. 62

7.7.2 Mass Spectrometry: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 62

7.8 Others. 63

7.8.1 Overview.. 63

7.8.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 63

8. Global Pharmacogenomics Market Revenue and Forecasts To 2028– by Application 64

8.1 Overview. 64

8.2 Global Pharmacogenomics Market Share by Application- 2021 & 2028 (%) 64

8.3 Drug Discovery. 65

8.3.1 Overview.. 65

8.3.2 Drug Discovery: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 65

8.4 Oncology. 66

8.4.1 Overview.. 66

8.4.2 Oncology: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 66

8.5 Neurology & Psychiatry. 67

8.5.1 Overview.. 67

8.5.2 Neurology & Psychiatry: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 67

8.6 Pain Management 68

8.6.1 Overview.. 68

8.6.2 Pain Management: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 68

8.7 Cardiovascular Disease. 69

8.7.1 Overview.. 69

8.7.2 Cardiovascular Disease: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 69

8.8 Others. 70

8.8.1 Overview.. 70

8.8.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 70

9. Pharmacogenomics Market Revenue and Forecasts To 2028 – End User 71

9.1 Overview. 71

9.2 Global Pharmacogenomics Market Share by End User - 2021 & 2028 (%) 71

9.3 Hospitals and Clinics. 72

9.3.1 Overview.. 72

9.3.2 Hospitals and Clinics: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 72

9.4 Biopharmaceutical Companies. 73

9.4.1 Overview.. 73

9.4.2 Biopharmaceuticals Companies: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 73

9.5 CROs and CDMOs. 74

9.5.1 Overview.. 74

9.5.2 CROs and CDMOs: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 74

9.6 Others. 75

9.6.1 Overview.. 75

9.6.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 75

10. Pharmacogenomics Market Revenue and Forecasts to 2028 – Geographical Analysis 76

10.1 North America: Pharmacogenomics Market 76

10.1.1 Overview.. 76

10.1.2 North America: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 77

10.1.3 North America: Pharmacogenomics Market, by Technology, 2019–2028 (US$ Million) 77

10.1.3.1 North America: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 78

10.1.4 North America: Pharmacogenomics Market, by Application, 2019–2028 (US$ Million) 78

10.1.5 North America: Pharmacogenomics Market, by End-User, 2019–2028 (US$ Million) 79

10.1.6 North America: Pharmacogenomics Market, by Country, 2021 & 2028 (%) 79

10.1.6.1 US: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 79

10.1.6.1.1 Overview.. 79

10.1.6.1.2 US: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 80

10.1.6.1.3 US: Pharmacogenomics Market, by Technology, 2019–2028 (US$ Million) 80

10.1.6.1.3.1 US: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 81

10.1.6.1.4 US: Pharmacogenomics Market, by Application, 2019–2028 (US$ Million) 81

10.1.6.1.5 US: Pharmacogenomics Market, by End-User, 2019–2028 (US$ Million) 82

10.1.6.2 Canada: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 82

10.1.6.2.1 Overview.. 82

10.1.6.2.2 Canada: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 83

10.1.6.2.3 Canada: Pharmacogenomics Market, by Technology, 2019–2028 (US$ Million) 83

10.1.6.2.3.1 Canada: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 84

10.1.6.2.4 Canada: Pharmacogenomics Market, by Application, 2019–2028 (US$ Million) 84

10.1.6.2.5 Canada: Pharmacogenomics Market, by End-User, 2019–2028 (US$ Million) 85

10.1.6.3 Mexico: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 85

10.1.6.3.1 Overview.. 85

10.1.6.3.2 Mexico: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 86

10.1.6.3.3 Mexico: Pharmacogenomics Market, by Technology, 2019–2028 (US$ Million) 86

10.1.6.3.3.1 Mexico: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 87

10.1.6.3.4 Mexico: Pharmacogenomics Market, by Application, 2019–2028 (US$ Million) 87

10.1.6.3.5 Mexico: Pharmacogenomics Market, by End-User, 2019–2028 (US$ Million) 88

10.2 Europe: Pharmacogenomics Market 89

10.2.1 Overview.. 89

10.2.2 Europe: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 90

10.2.3 Europe: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 90

10.2.3.1 Europe: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 91

10.2.4 Europe: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 91

10.2.5 Europe: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 92

10.2.6 Europe: Pharmacogenomics Market, by Country, 2021 & 2028 (%) 92

10.2.6.1 Germany: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 92

10.2.6.1.1 Overview.. 92

10.2.6.1.2 Germany: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 93

10.2.6.1.3 Germany: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 93

10.2.6.1.3.1 Germany: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 94

10.2.6.1.4 Germany: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 94

10.2.6.1.5 Germany: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 95

10.2.6.2 France: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 95

10.2.6.2.1 Overview.. 95

10.2.6.2.2 France: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 96

10.2.6.2.3 France: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 96

10.2.6.2.3.1 France: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 97

10.2.6.2.4 France: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 97

10.2.6.2.5 France: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 98

10.2.6.3 UK: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 98

10.2.6.3.1 Overview.. 98

10.2.6.3.2 UK: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 99

10.2.6.3.3 UK: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 99

10.2.6.3.3.1 UK: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 100

10.2.6.3.4 UK: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 100

10.2.6.3.5 UK: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 101

10.2.6.4 Italy: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 101

10.2.6.4.1 Overview.. 101

10.2.6.4.2 Italy: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 102

10.2.6.4.3 Italy: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 102

10.2.6.4.3.1 Italy: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 103

10.2.6.4.4 Italy: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 103

10.2.6.4.5 Italy: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 104

10.2.6.5 Spain: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 104

10.2.6.5.1 Overview.. 104

10.2.6.5.2 Spain: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 105

10.2.6.5.3 Spain: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 105

10.2.6.5.3.1 Spain: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 106

10.2.6.5.4 Spain: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 106

10.2.6.5.5 Spain: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 107

10.2.6.6 Rest of Europe: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 107

10.2.6.6.1 Overview.. 107

10.2.6.6.2 Rest of Europe: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 108

10.2.6.6.3 Rest of Europe: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 108

10.2.6.6.3.1 Rest of Europe: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 109

10.2.6.6.4 Rest of Europe: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 109

10.2.6.6.5 Rest of Europe: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 110

10.3 Asia Pacific Pharmacogenomics Market Revenue and Forecasts To 2028. 111

10.3.1 Overview.. 111

10.3.2 Asia Pacific Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 112

10.3.3 Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 112

10.3.3.1 Asia Pacific: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 113

10.3.4 Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 113

10.3.5 Asia Pacific: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 114

10.3.6 Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%) 114

10.3.6.1 Japan: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 114

10.3.6.1.1 Overview.. 114

10.3.6.1.2 Japan: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 115

10.3.6.1.3 Japan: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 115

10.3.6.1.3.1 Japan: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 116

10.3.6.1.4 Japan: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 116

10.3.6.1.5 Japan: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 117

10.3.6.2 China: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 117

10.3.6.2.1 Overview.. 117

10.3.6.2.2 China: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 118

10.3.6.2.3 China: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 118

10.3.6.2.3.1 China: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 119

10.3.6.2.4 China: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 119

10.3.6.2.5 China: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 120

10.3.6.3 India Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 120

10.3.6.3.1 Overview.. 120

10.3.6.3.2 India: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 121

10.3.6.3.3 India: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 121

10.3.6.3.3.1 India: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 122

10.3.6.3.4 India: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 122

10.3.6.3.5 India: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 123

10.3.6.4 South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 123

10.3.6.4.1 Overview.. 123

10.3.6.4.2 South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 124

10.3.6.4.3 South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 124

10.3.6.4.3.1 South Korea: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 125

10.3.6.4.4 South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 125

10.3.6.4.5 South Korea: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 126

10.3.6.5 Australia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 126

10.3.6.5.1 Overview.. 126

10.3.6.5.2 Australia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 127

10.3.6.5.3 Australia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 127

10.3.6.5.3.1 Australia: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 128

10.3.6.5.4 Australia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 128

10.3.6.5.5 Australia: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 129

10.3.6.6 Rest of Asia Pacific: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 129

10.3.6.6.1 Overview.. 129

10.3.6.6.2 Rest of Asia Pacific: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 130

10.3.6.6.3 Rest of Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 130

10.3.6.6.3.1 Rest of Asia Pacific: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 131

10.3.6.6.4 Rest of Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 131

10.3.6.6.5 Rest of Asia Pacific: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 132

10.4 Middle East & Africa Pharmacogenomics Market Revenue and Forecasts To 2028. 133

10.4.1 Overview.. 133

10.4.2 Middle East & Africa Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 134

10.4.3 Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 134

10.4.3.1 Middle East & Africa: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 135

10.4.4 Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 135

10.4.5 Middle East & Africa: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 136

10.4.6 Middle East & Africa Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%) 136

10.4.6.1 UAE: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 136

10.4.6.1.1 Overview.. 136

10.4.6.1.2 UAE: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 137

10.4.6.1.3 UAE: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 137

10.4.6.1.3.1 UAE: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 138

10.4.6.1.4 UAE: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 138

10.4.6.1.5 UAE: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 139

10.4.6.2 Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 139

10.4.6.2.1 Overview.. 139

10.4.6.2.2 Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 140

10.4.6.2.3 Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 140

10.4.6.2.3.1 Saudi Arabia: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 141

10.4.6.2.4 Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 141

10.4.6.2.5 Saudi Arabia: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 142

10.4.6.3 South Africa: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 142

10.4.6.3.1 Overview.. 142

10.4.6.3.2 South Africa Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 143

10.4.6.3.3 South Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 143

10.4.6.3.3.1 South Africa: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 144

10.4.6.3.4 South Africa: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 144

10.4.6.3.5 South Africa: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 145

10.4.6.4 Rest of Middle East and Africa: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 145

10.4.6.4.1 Overview.. 145

10.4.6.4.2 Rest of Middle East and Africa: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 145

10.4.6.4.3 Rest of Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 146

10.4.6.4.3.1 Rest of Middle East & Africa: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 146

10.4.6.4.4 Rest of Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 147

10.4.6.4.5 Rest of Middle East and Africa: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 147

10.5 South And Central America Pharmacogenomics Market Revenue and Forecasts To 2028. 149

10.5.1 Overview.. 149

10.5.2 South and Central America Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 150

10.5.3 South and Central America Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 150

10.5.3.1 South and Central America: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 151

10.5.4 South and Central America: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 151

10.5.5 South and Central America: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 152

10.5.6 South and Central America Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%) 152

10.5.6.1 Argentina Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 152

10.5.6.1.1 Overview.. 152

10.5.6.1.2 Argentina Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 153

10.5.6.1.3 Argentina: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 153

10.5.6.1.3.1 Argentina: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 154

10.5.6.1.4 Argentina: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 154

10.5.6.1.5 Argentina: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 155

10.5.6.2 Brazil: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 155

10.5.6.2.1 Overview.. 155

10.5.6.2.2 Brazil: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 156

10.5.6.2.3 Brazil: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 156

10.5.6.2.3.1 Brazil: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 157

10.5.6.2.4 Brazil: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 157

10.5.6.2.5 Brazil: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 158

10.5.6.3 Rest of South and Central America: Pharmacogenomics Market– Revenue and Forecast to 2028 (USD Mn) 158

10.5.6.3.1 Overview.. 158

10.5.6.3.2 Rest of South and Central America: Pharmacogenomics Market– Revenue and Forecast to 2028 (USD Mn) 159

10.5.6.3.3 Rest of South & Central America: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 159

10.5.6.3.3.1 Rest of South & Central America: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 160

10.5.6.3.4 Rest of South & Central America: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 160

10.5.6.3.5 Rest of South and Central America: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 161

11. Impact of COVID-19 Pandemic on Global Pharmacogenomics Market 162

11.1 North America: Impact Assessment of COVID-19 Pandemic. 162

11.2 Europe: Impact Assessment of COVID-19 Pandemic. 163

11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic. 164

11.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic. 165

11.5 South and Central America: Impact Assessment of COVID-19 Pandemic. 166

12. Industry Landscape 167

12.1 Overview. 167

12.2 Growth Strategies in the Pharmacogenomics Market 167

12.3 Organic Developments. 168

12.3.1 Overview.. 168

12.4 Inorganic Developments. 170

12.4.1 Overview.. 170

13. Company Profiles 172

13.1 Abbott 172

13.1.1 Key Facts. 172

13.1.2 Business Description. 172

13.1.3 Products and Services. 172

13.1.4 Financial Overview.. 173

13.1.5 SWOT Analysis. 174

13.1.6 Key Developments. 175

13.2 F. HOFFMANN-LA ROCHE LTD. 176

13.2.1 Key Facts. 176

13.2.2 Business Description. 176

13.2.3 Products and Services. 176

13.2.4 Financial Overview.. 177

13.2.5 SWOT Analysis. 179

13.2.6 Key Developments. 179

13.3 Oxford Nanopore Technologies. 180

13.3.1 Key Facts. 180

13.3.2 Business Description. 180

13.3.3 Products and Services. 180

13.3.4 Financial Overview.. 180

13.3.5 SWOT Analysis. 181

13.3.6 Key Developments. 181

13.4 THERMO FISHER SCIENTIFIC INC. 182

13.4.1 Key Facts. 182

13.4.2 Business Description. 182

13.4.3 Products and Services. 182

13.4.4 Financial Overview.. 183

13.4.5 SWOT Analysis. 184

13.4.6 Key Developments. 185

13.5 Illumina, Inc. 186

13.5.1 Key Facts. 186

13.5.2 Business Description. 186

13.5.3 Products and Services. 187

13.5.4 Financial Overview.. 187

13.5.5 SWOT Analysis. 188

13.5.6 Key Developments. 189

13.6 QIAGEN. 190

13.6.1 Key Facts. 190

13.6.2 Business Description. 190

13.6.3 Products and Services. 190

13.6.4 Financial Overview.. 191

13.6.5 SWOT Analysis. 192

13.6.6 Key Developments. 193

13.7 Agilent Technologies, Inc. 194

13.7.1 Key Facts. 194

13.7.2 Business Description. 194

13.7.3 Products and Services. 195

13.7.4 Financial Overview.. 195

13.7.5 SWOT Analysis. 197

13.7.6 Key Developments. 197

13.8 Myriad Genetics, Inc. 198

13.8.1 Key Facts. 198

13.8.2 Business Description. 198

13.8.3 Products and Services. 198

13.8.4 Financial Overview.. 199

13.8.5 SWOT Analysis. 200

13.8.6 Key Developments. 200

13.9 Admera Health. 201

13.9.1 Key Facts. 201

13.9.2 Business Description. 201

13.9.3 Products and Services. 201

13.9.4 Financial Overview.. 201

13.9.5 SWOT Analysis. 202

13.9.6 Key Developments. 202

13.10 Dynamic DNA Laboratories. 203

13.10.1 Key Facts. 203

13.10.2 Business Description. 203

13.10.3 Products and Services. 203

13.10.4 Financial Overview.. 203

13.10.5 SWOT Analysis. 204

13.10.6 Key Developments. 204

14. Appendix 205

14.1 About The Insight Partners. 205

14.2 Glossary of Terms. 205

LIST OF TABLES

Table 1. North America Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 77

Table 2. North America: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 78

Table 3. North America Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (USD Million) 78

Table 4. US Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 80

Table 5. US Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 81

Table 6. US Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 81

Table 7. US Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 82

Table 8. Canada: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 83

Table 9. Canada: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 84

Table 10. Canada Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 84

Table 11. Canada Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 85

Table 12. Mexico: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 86

Table 13. Mexico: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 87

Table 14. Mexico Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 87

Table 15. Mexico Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 88

Table 16. Europe: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 90

Table 17. Europe: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 91

Table 18. Europe: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 91

Table 19. Europe: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 92

Table 20. Germany: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 93

Table 21. Germany: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 94

Table 22. Germany: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 94

Table 23. Germany: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 95

Table 24. France: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 96

Table 25. France: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 97

Table 26. France: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 97

Table 27. France: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 98

Table 28. UK: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 99

Table 29. UK: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 100

Table 30. UK: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 100

Table 31. UK: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 101

Table 32. Italy: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 102

Table 33. Italy: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 103

Table 34. Italy: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 103

Table 35. Italy: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 104

Table 36. Spain: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 105

Table 37. Spain: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 106

Table 38. Spain: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 106

Table 39. Spain: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 107

Table 40. Rest of Europe: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 108

Table 41. Rest of Europe: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 109

Table 42. Rest of Europe: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 109

Table 43. Rest of Europe: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 110

Table 44. Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million). 112

Table 45. Asia Pacific: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 113

Table 46. Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 113

Table 47. Asia Pacific: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 114

Table 48. Japan: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 115

Table 49. Japan: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 116

Table 50. Japan: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 116

Table 51. Japan: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 117

Table 52. China: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 118

Table 53. China: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 119

Table 54. China: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 119

Table 55. China: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 120

Table 56. India: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 121

Table 57. India: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 122

Table 58. India: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 122

Table 59. India: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 123

Table 60. South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 124

Table 61. South Korea: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 125

Table 62. South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 125

Table 63. South Korea: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 126

Table 64. Australia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 127

Table 65. Australia: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 128

Table 66. Australia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 128

Table 67. Australia: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 129

Table 68. Rest of Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 130

Table 69. Rest of Asia Pacific: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 131

Table 70. Rest of Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 131

Table 71. Rest of Asia Pacific: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 132

Table 72. Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 134

Table 73. Middle East & Africa: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 135

Table 74. Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 135

Table 75. Middle East & Africa: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 136

Table 76. UAE: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 137

Table 77. UAE: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 138

Table 78. UAE: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 138

Table 79. UAE: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 139

Table 80. Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 140

Table 81. Saudi Arabia: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 141

Table 82. Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 141

Table 83. Saudi Arabia: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 142

Table 84. South Africa Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 143

Table 85. South Africa: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 144

Table 86. South Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 144

Table 87. South Africa: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 145

Table 88. Rest of Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 146

Table 89. Rest of Middle East & Africa: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 146

Table 90. Rest of Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 147

Table 91. Rest of Middle East and Africa: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 147

Table 92. South and Central America Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 150

Table 93. South and Central America: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 151

Table 94. South and Central America: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 151

Table 95. South and Central America: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 152

Table 96. Argentina: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 153

Table 97. Argentina: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 154

Table 98. Argentina: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 154

Table 99. Argentina: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 155

Table 100. Brazil: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 156

Table 101. Brazil: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 157

Table 102. Brazil: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 157

Table 103. Brazil: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 158

Table 104. Rest of South & Central America: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 159

Table 105. Rest of South & Central America: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 160

Table 106. Rest of South & Central America: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 160

Table 107. Rest of South and Central America: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 161

Table 108. Organic Developments Done By Companies. 168

Table 109. Inorganic Developments Done By Companies. 170

Table 110. Glossary of Terms. 205

LIST OF FIGURES

Figure 1. Pharmacogenomics Market Segmentation. 30

Figure 2. Pharmacogenomics Market, By Region. 31

Figure 3. Global Pharmacogenomics Market Overview. 34

Figure 4. PCR Segment Held Largest Share of Technology Segment in Pharmacogenomics Market 35

Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period. 36

Figure 6. Pharmacogenomics Market, by Geography (US$ Million) 37

Figure 7. Global Pharmacogenomics Market- Leading Country Markets (US$ Million) 38

Figure 8. Global Pharmacogenomics Market, Industry Landscape. 39

Figure 9. North America: PEST Analysis. 43

Figure 10. Europe: PEST Analysis. 44

Figure 11. Asia Pacific: PEST Analysis. 44

Figure 12. Middle East And Africa: PEST Analysis. 45

Figure 13. South And Central America: PEST Analysis. 45

Figure 14. Experts Opinion. 46

Figure 15. Global Pharmacogenomics Market– Revenue Forecast and Analysis – 2021 - 2028. 50

Figure 16. Global Pharmacogenomics Market – By Geography Forecast and Analysis – 2021 - 2028. 51

Figure 17. Market Positioning of Key Players in Global Pharmacogenomics Market 51

Figure 18. Global Pharmacogenomics Market Share by Segment - 2021 & 2028 (%) 53

Figure 19. Polymerase Chain Reaction: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 54

Figure 20. Real Time PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 55

Figure 21. Standard PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 56

Figure 22. Digital PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 57

Figure 23. Sequencing: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 59

Figure 24. Microarray: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 60

Figure 25. Gel Electrophoresis: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 61

Figure 26. Mass Spectrometry: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 62

Figure 27. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 63

Figure 28. Global Pharmacogenomics Market Share by Application- 2021 & 2028 (%) 64

Figure 29. Drug Discovery: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 65

Figure 30. Oncology: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 66

Figure 31. Neurology & Psychiatry: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 67

Figure 32. Pain Management: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 68

Figure 33. Cardiovascular Disease: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 69

Figure 34. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 70

Figure 35. Global Pharmacogenomics Market Share by End User - 2021 & 2028 (%) 71

Figure 36. Hospital and Clinics: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 72

Figure 37. Biopharmaceutical Companies: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 73

Figure 38. CROs and CDMOs: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 74

Figure 39. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 75

Figure 40. North America: Pharmacogenomics Market, by Key Country – Revenue (2021) (US$ Million) 76

Figure 41. North America Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 77

Figure 42. North America: Pharmacogenomics Market, by Country, 2021 & 2028 (%) 79

Figure 43. US: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 80

Figure 44. Canada: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 83

Figure 45. Mexico: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 86

Figure 46. Europe: Pharmacogenomics Market, by Key Country – Revenue (2021) (US$ Million) 89

Figure 47. Europe: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 90

Figure 48. Europe: Pharmacogenomics Market, by Country, 2021 & 2028 (%) 92

Figure 49. Germany: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 93

Figure 50. France: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 96

Figure 51. UK: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 99

Figure 52. Italy: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 102

Figure 53. Spain: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 105

Figure 54. Rest of Europe: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 108

Figure 55. Asia Pacific Pharmacogenomics Market Overview, by Country (2021) 111

Figure 56. Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 112

Figure 57. Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%) 114

Figure 58. Japan: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 115

Figure 59. China: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 118

Figure 60. India: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 121

Figure 61. South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 124

Figure 62. Australia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 127

Figure 63. Rest of Asia Pacific: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 130

Figure 64. Middle East & Africa Pharmacogenomics Market Revenue Overview, by Country, 2021 (US$ Million) 133

Figure 65. Middle East & Africa Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 134

Figure 66. Middle East & Africa Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%) 136

Figure 67. UAE: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 137

Figure 68. Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 140

Figure 69. South Africa: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 143

Figure 70. Rest of Middle East and Africa: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 146

Figure 71. South and Central America Pharmacogenomics Market Revenue Overview, by Country, 2021 (US$ Million) 149

Figure 72. South and Central America Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 150

Figure 73. South and Central America Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%) 152

Figure 74. Argentina Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 153

Figure 75. Brazil: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 156

Figure 76. Rest of South and Central America: Pharmacogenomics Market– Revenue and Forecast to 2028 (USD Mn) 159

Figure 77. Impact of COVID-19 Pandemic in North America Country Markets. 162

Figure 78. Impact of COVID-19 Pandemic on Sequencing Reagents Market in European Countries. 163

Figure 79. Impact of COVID-19 Pandemic in Asia Pacific Country Markets. 164

Figure 80. Impact of COVID-19 Pandemic on Sequencing Reagents Market in Rest of the World. 165

Figure 81. Impact of COVID-19 Pandemic in South and Central America Country Markets. 166

Figure 82. Growth Strategies in the Pharmacogenomics Market 167

The List of Companies - Pharmacogenomics Market

  1. F. Hoffmann-la Roche Ltd
  2. Abbott
  3. Oxford Nanopore Technologies
  4. Thermo Fisher Scientific Inc.
  5. Illumina, Inc.
  6. QIAGEN
  7. Agilent Technologies, Inc.
  8. Myriad Genetics, Inc.
  9. Admera Health
  10. Dynamic DNA Laboratories

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the pharmacogenomics market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global Intradermal Injection market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distributions.
TIPRE00007564
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.


Speak To Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550
    GET FREE SAMPLE PDF

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount